Welcome to our dedicated page for Barinthus Biotherapeutics plc news (Ticker: vacc), a resource for investors and traders seeking the latest updates and insights on Barinthus Biotherapeutics plc stock.
Barinthus Biotherapeutics (NASDAQ: BRNS) is a clinical-stage innovator developing T cell immunotherapies for chronic diseases and cancer. This news hub provides investors and healthcare professionals with essential updates on clinical trials, regulatory developments, and scientific breakthroughs.
Our curated collection features verified updates on Barinthus’ pipeline programs including VTP-300 for Hepatitis B and VTP-200 targeting HPV. Track progress across all development stages – from preclinical research to late-phase trials – with timely reports on study initiations, data readouts, and partnership announcements.
Key focus areas include updates on the company’s proprietary platforms like ChAdOx and MVA vector systems, financial position updates, and strategic collaborations. Recent highlights feature Phase 2 HBV trial developments and manufacturing scale-up initiatives.
Bookmark this page for structured access to Barinthus Biotherapeutics’ latest advancements in immune-guided therapies. All content is sourced from company filings and official communications to ensure reliability.
DelveInsight's 'Prostate Cancer Pipeline Insight – 2023' report highlights significant advancements in the prostate cancer therapeutics market. With over 170 companies developing more than 200 pipeline therapies, key players include Merck, Pfizer, and AstraZeneca. Recent notable developments include Fusion Pharmaceuticals acquiring a Phase II trial drug and Corbus Pharmaceuticals licensing an antibody drug targeting Nectin-4. The report underscores growing government funding and awareness initiatives as factors driving market growth, essential given that prostate cancer represents a leading cause of cancer death among men.
Vaccitech plc (NASDAQ: VACC) has appointed Dr. Nadège Pelletier as its new Chief Scientific Officer (CSO) to spearhead its expanding clinical pipeline. With over 15 years of experience in immunology and infectious diseases, Dr. Pelletier transitions into this role after Dr. Tom Evans, who will remain with the company as a consultant. CEO Bill Enright expressed confidence in Dr. Pelletier's capabilities to lead drug discovery and collaborations. The company anticipates significant clinical milestones in 2023, focusing on developing therapies for chronic infectious diseases and cancer, including candidates such as VTP-300 and VTP-200.
The Europe human papillomavirus (HPV) vaccine market is projected to grow from
Queen of Raw, a climate fintech company, achieved a remarkable 650% growth in 2022, addressing the $288B excess inventory problem, which often ends up as waste. Backed by Future Planet Capital, the company offers Materia MX, a SaaS solution that allows businesses to manage and recycle surplus inventory. This approach not only mitigates financial losses (up to 15% impact on profits) but also contributes to environmental sustainability. Their initiatives have saved over 1 billion gallons of water and demonstrated significant cost savings for Fortune 500 clients.
Vaccitech plc (NASDAQ: VACC) reported its financial results for Q3 2022, with revenues of $6.2 million, down from $17.1 million in Q2, primarily due to a lack of milestone achievements. The company continues its clinical advancements, including the dosing of the first patient in its Phase 2b trial for VTP-300 in HBV. Cash reserves stood at $200.1 million, extending its cash runway into Q1 2025, supported by royalty and milestone payments from AstraZeneca's Vaxzevria®. Net income for the quarter was $8.2 million, down from $15.7 million in Q2 2022.
Vaccitech plc (NASDAQ: VACC) announced that its CEO, Bill Enright, and CFO, Gemma Brown, will present at two upcoming investment conferences. The Jefferies London Healthcare Conference runs from November 15-17, featuring a fireside chat on November 15 at 17:35 GMT. The Piper Sandler 34th Annual Healthcare Conference will follow from November 29-December 1, where the company will deliver a company overview at 09:50 EST on December 1. Vaccitech will also engage in one-on-one investor meetings during these events.
Vaccitech has announced positive interim results from its Phase 1b/2a trial of VTP-300, targeting chronic hepatitis B (HBV), showing sustained reductions in hepatitis B surface antigen (HBsAg) among patients. In a cohort of 55 patients, significant declines in HBsAg were noted, especially in those with lower initial levels. The trial reported no serious adverse effects, and CD8+ T cell responses were robust. The next update is expected in Q2 2023, with ongoing studies evaluating further booster doses and combinations with other treatments.
Vaccitech plc (NASDAQ: VACC) announced a presentation regarding its Phase 1b/2a study of VTP-300, an immunotherapy for chronic hepatitis B, at the AASLD - The Liver Meeting® from November 4-8, 2022. The poster details the therapeutic vaccination's safety, tolerability, and ability to stimulate immune responses, as well as durable reductions in hepatitis B surface antigen. The study combines an adenoviral vector with a pox virus and is presented by Dr. Young-Suk Lim. Key executives will also attend the meeting for potential partnerships.
Vaccitech plc (NASDAQ: VACC) announced the commencement of dosing in the HBV003 Phase 2b clinical trial, evaluating the safety and efficacy of VTP-300 combined with a low-dose anti-PD-1 antibody for chronic hepatitis B patients. The trial aims to enroll 120 patients across the Asia-Pacific region. VTP-300 demonstrated promising results in the prior HBV002 study, showing significant reductions in Hepatitis B surface Antigen levels and robust activation of immune cells. The study seeks to identify an optimal treatment regimen and progress towards a functional cure for millions affected by chronic HBV.
Vaccitech plc (NASDAQ: VACC) reported significant findings on its SNAPvax platform, particularly in the treatment of cancer. Research from NIH demonstrated that IV administration of SNAPvax can activate T cells and reverse the tumor microenvironment suppression, enhancing tumor regression. An IND submission for SNAPvax candidate VTP-1100, targeting HPV-related cancers, is planned for the first half of 2023. This publication underlines Vaccitech's leadership in immunotherapy, showcasing their novel approach to T cell priming and activation.
